Clinical Trials
295
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (183 trials with phase data)• Click on a phase to view related trials
A Clinical Study of Chinese Herbal Formula TJAOA103 in Treating Genitourinary Syndrome of Menopause
- Conditions
- Genitourinary Syndrome of Menopause (GSM)
- Interventions
- Drug: TJAOA103
- First Posted Date
- 2025-09-08
- Last Posted Date
- 2025-09-08
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 113
- Registration Number
- NCT07160127
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China
To Explore the Value of New MR Technology in Non-invasive Quantitative Assessment of Systemic Metabolism, Disease Status and Prognosis in Patients With Metabolic-Associated Fatty Liver Disease
- Conditions
- Nonalcoholic Fatty Liver DiseaseMetabolic-associated Fatty Liver Disease
- First Posted Date
- 2025-09-02
- Last Posted Date
- 2025-09-02
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT07149571
- Locations
- 🇨🇳
Tongji hospital, Wuhan, Hubei, China
To Explore the Application Value of Magnetic Resonance Imaging in Noninvasive Quantitative Evaluation of Graft Function and Systemic Metabolism After Renal Transplantation
- Conditions
- Kidney Transplant Failure and RejectionTransplantation, KidneyKidney Transplant Dysfunction
- First Posted Date
- 2025-08-28
- Last Posted Date
- 2025-08-28
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 500
- Registration Number
- NCT07145944
Radiomics-Based Non-Invasive MRI Differentiation of Uterine Sarcomas and Fibroids
- Conditions
- Uterine FibroidUterine SarcomaDiagnose DiseaseAI (Artificial Intelligence)
- First Posted Date
- 2025-08-19
- Last Posted Date
- 2025-08-19
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 520
- Registration Number
- NCT07129005
- Locations
- 🇨🇳
Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China
The Application of an AI-driven Multimodal Predictive Model for Cognitive Impairment in Patients With Type 2 Diabetes Mellitus
- Conditions
- Cognitive Dysfunction
- First Posted Date
- 2025-08-17
- Last Posted Date
- 2025-08-17
- Lead Sponsor
- Tongji Hospital
- Target Recruit Count
- 5000
- Registration Number
- NCT07128186
- Locations
- 🇨🇳
Minda Hospital Affiliated to Hubei Minzu University, Enshi, Hubei, China
🇨🇳Huanggang Central Hospital, Huanggang, Hubei, China
🇨🇳Huangshi Central Hospital, Huangshi, Hubei, China
- Prev
- 1
- 2
- 3
- 4
- 5
- 59
- Next
News
Novel In Vivo CD19 CAR-T Therapy Achieves Complete Remission in Aggressive DLBCL Without Lymphodepletion
A heavily pretreated patient with relapsed/refractory diffuse large B-cell lymphoma achieved complete remission within 28 days following a single dose of Genocury Biotech's novel in vivo CD19 CAR-T therapy.
Sintilimab Plus Bevacizumab Shows Promise in Relapsed Ovarian Clear Cell Carcinoma
A phase II trial (INOVA) found that sintilimab combined with bevacizumab demonstrated activity in patients with relapsed or persistent ovarian clear cell carcinoma.